Knoepfler Lab

10/11/2026

Weekly regenerative med reads: stem cell and peptides via RFK Jr., Urnov vs. Tie exchange fire, med centers cash in on longevity, the end for Caribou https://ipscell.com/2026/10/weekly-reads-stem-cell-and-peptides-via-rfk-jr-urnov-vs-tie-exchange-fire-med-centers-cash-in-on-longevity-the-end-for-caribou

Professor's weekly reads: stem cell and peptides via RFK Jr., med centers cash in on longevity, Caribou, Urnov vs. Tie exchange fire

10/09/2026

Pop peptide politics: RFK Jr. reportedly will force quick access to unapproved peptide drugs like BPC-157 before required rulemaking https://ipscell.com/2026/10/pop-peptide-politics-rfk-jr-reportedly-will-force-quick-access-before-required-rulemaking Putting compounding and telehealth profits & ideology over biomedical science

RFK Jr. reportedly will force quick access to sketchy peptides, part of an apparent plan to benefit peptide compounding and wellness firms.

10/04/2026

Weekly regenerative reads: AI grant review, sham orgs trick academics, Origin Genomics, CRISPR babies, H3.3 K27M https://ipscell.com/2026/10/weekly-reads-ai-doing-grant-review-sham-orgs-trick-academics-origin-genomics-crispr-babies

Biologists' Weekly reads: AI grant review, sham orgs trick star researchers, Origin Genomics & CRISPR babies, false hope.

10/01/2026

Wild Scott Carney stem cell video with buffet of topics: Adeel Kahn, Kardashians, Muse cells, Liveyon, Platinum Biologics, & more https://ipscell.com/2026/10/wild-scott-carney-stem-cell-buffet-video-adeel-kahn-kardashians-muse-cells-liveyon-platinum-biologics-more Kind of tabloidy style video, but nice to see someone else tackling the unproven clinic world

Stem cell biologist discusses wild Scott Carney video on Adeel Kahn that touches on celebs, Dezawa Muse Cells, Liveyon, Platinum Biologics.

09/27/2026

Weekly stem cell & reads: $100B NIH budget dream, Sholto David on YouTube, Jun Takahashi award, Muse cell developments

What should the NIH budget be these days? Certainly higher than it is, but what would the ideal level be? One of my weekly reads is a proposal for $100B in NIH funding. All things considered, that seems reasonable to me. NIH is a massive engine of innovation for our country that generates huge numbe...

09/22/2026

My lab is raising money for childhood cancer research via the Alex's Lemonade Stand Foundation, a great organization. We're not 100% sure but at least some of this might go to our lab's pediatric brain tumor research. Either way it will help move important research forward to help kids. Would you please help our team out either with a donation (tax deductible) or pledging based on miles we run, walk, etc.? Here's my page: https://www.alexslemonade.org/2026/labturtles/member/329921 Thanks!

Alex's Lemonade Stand Foundation for Childhood Cancer work333 E. Lancaster Ave, #414 • Wynnewood, PA 19096 USA • Ph: work610.649.3034 • Fax: 610.649.3038

09/20/2026

Weekly regenerative reads: Longeveron MSC trial misses primary endpoint, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes https://ipscell.com/2026/09/weekly-reads-longeveron-trial-disappoints-crispr-ancestor-vipr-distinct-human-brain-progenitors-fda-staffing-woes

09/16/2026

Amid patient deaths and adverse events Japan needs to tackle its unproven regenerative clinics https://ipscell.com/2026/09/amid-patient-deaths-and-adverse-events-japan-needs-to-tackle-its-unproven-regenerative-clinics Some researchers there are rightly pushing for change

Biologist discusses how Japan stem cell clinic oversight changes could be coming after patient harms including deaths.

09/13/2026

Weekly regenerative & stem cell reads: suite of reprogramming news, cancer trial reform, zombie retracted papers https://ipscell.com/2026/09/weekly-reads-suite-of-reprogramming-news-cancer-trial-reform-zombie-retracted-papers

Professor's weekly regenerative reads: suite of reprogramming news, obstacle to cancer cures, zombie retracted papers.

09/09/2026

Quick perspectives on Karim Mikhail as new permanent CBER director https://ipscell.com/2026/09/quick-perspectives-on-karim-mikhail-as-permanent-cber-director Tough time to be the biologics branch leader. He has some support among FDA folks